CLOSE

Specials

I agree We use cookies on this website to enhance your user experience. By clicking any link on this page you are giving your consent for us to set cookies. More info

Skip to: Curated Story Group 1
lifesciencesreview
US
EUROPE
APAC
CANADA
  • US
    • US
    • EUROPE
    • APAC
    • CANADA
    • LATAM
  • Home
  • Contributors
  • News
  • Conferences
  • Newsletter
  • Whitepapers
  • Magazine
×
#

Life Science Review Weekly Brief

Be first to read the latest tech news, Industry Leader's Insights, and CIO interviews of medium and large enterprises exclusively from Life Science Review

Subscribe

loading

Thank you for Subscribing to Life Science Review Weekly Brief

  • Home
  • News

Recommended picks

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Key Biotech Applications In Agriculture

Key Biotech Applications In Agriculture

Here's The List Of Top Biotech Stocks To Buy In 2022

Here's The List Of Top Biotech Stocks...

How Does Biotechnology Help Humans?

How Does Biotechnology Help Humans?

How Does Biotechnology Help Agriculture Sector Reap Benefits

How Does Biotechnology Help...

Tryp Therapeutics Breaks New Grounds in Investigational Drugs

Tryp Therapeutics Breaks New Grounds...

Biotechnology in Agriculture: Key Applications and Significance to Know

Biotechnology in Agriculture: Key...

DNA Sequencing Everything You Need to Know

DNA Sequencing Everything You Need to...

The Applications of Data Analytics in Biotechnology

The Applications of Data Analytics in...

Grzegorz Sarek Hired as the Vice President of Research by EG 427

Life Sciences Review Life Sciences Review | Thursday, September 30, 2021
Tweet

Grzegorz Sarek, EG 427’s new Vice president of research, will be looking after the company’s R&D efforts.


FREMONT, CA: Grzegorz Sarek has been named Vice President of Research by EG 427. Dr. Sarek has accumulated a plethora of experience in the domains of virology, gene therapy, translational biomedicine, and cancer biology during the course of his career. He will lead the company's R&D efforts as it establishes the only European platform for gene therapy that takes use of HSV-1's innate homing and latency features.


“We are excited to welcome Grzegorz Sarek into the EG 427 team to lead our laboratory and R&D activities,” said Alberto Epstein, Ph.D., Chief Scientific Officer at EG 427. “A great addition to our team, Grzegorz is an accomplished virologist as evidenced by his impressive publication track record. He has an extensive knowledge of Herpes family viruses and a considerable experience in viral gene transfer methods using AAV-based vectors, which, together with his managing skills, are tremendous assets for EG 427 to continue developing pinpoint gene therapy.”


Dr. Sarek was the director of Gene Therapy and Translational Research at DiNAQOR AG in Zurich before joining EG 427. DiNAQOR AG develops gene therapy solutions for inherited heart disease. He was previously a Principal Scientist in the field of single-stranded oligonucleotide therapeutics at F. Hoffmann-La Roche in Basel, Switzerland, and a Group Leader in Molecular Virology at Imperial College London, UK. Dr. Sarek received his Ph.D. in Oncology and Cancer Biology from the University of Helsinki's Faculty of Medicine in Finland, and his post-doctoral training in the field of DNA Damage Response at The Francis Crick Institute in London, United Kingdom.


"I see great potential in HSV-1-based gene therapy vectors as they present clear advantages with respect to other viral vectors, both in terms of safety and of gene delivery,” explained Grzegorz Sarek, Ph.D., now Vice President of Research at EG 427. “I am therefore very enthusiastic about joining EG 427 to contribute to the development of what I see as a rigorously devised and promising HSV-1 technology vector platform, and to have the opportunity to work with a remarkable management team and founders driven by the will to solve majors medical needs.”


Weekly Brief

loading
Top 10 Leading BioTech Solution Companies - 2021
> <
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue
  • Regulatory Services 2023

    Top Vendors

    Current Issue
  • Clinical Lab Equipment 2023

    Top Vendors

    Current Issue

Read Also

The Role of AI in Accurate Medical Writing

Patrik Renblad to Join Cantargia as Chief Financial Officer

Overview of the Life Sciences BPO Market

Dr. Zamaneh Mikhak Joins TFF Pharmaceutical as the New Chief Medical Officer

The Significance of AI in Medical Writing

The Importance of Technology in Multinational Clinical Research

Hepion Pharmaceuticals to Get a Total of $ 3.2 Million in Non-Dilutive Financing

Benefits that Medical Writing Offers

Loading...

Copyright © 2023 Life Sciences Review . All rights reserved. |  Subscribe |  About Us follow on linkedin

This content is copyright protected

However, if you would like to share the information in this article, you may use the link below:

https://www.lifesciencesreview.com/news/grzegorz-sarek-hired-as-the-vice-president-of-research-by-eg-427-nwid-582.html